Brief: Double Bond Pharmaceutical Presents Results From Study Evaluating Inofer
28/11/2019 07:07
Nov 28 (Reuters) - Double Bond Pharmaceutical International
AB (publ) DBPHAb.TE :
* CLINICAL TRIAL RESULTS INDICATE THAT INOFER MARKEDLY AND
SIGNIFICANTLY IMPROVED IRON UPTAKE, IRON SATURATION AND IRON
STORES IN PATIENTS WITH HEART FAILURE AND IRON DEFICIENCY
* RESULTS SHOW THAT INOFER GIVEN TWICE DAILY MARKEDLY AND
SIGNIFICANTLY IMPROVED IRON SATURATION AND IRON STORES IN
STUDIED PATIENTS
* PRIMARY AND SECONDARY OBJECTIVES OF CLINICAL TRIALS HAVE
THUS
BEEN ACHIEVED
* INOFER WAS WELL TOLERATED, PATIENT GROUP THAT RECEIVED
INOFER
DID EXPERIENCED SOME WELL-KNOWN AND MILD SIDE EFFECTS OF ORAL
IRON THERAP
* OVERALL, RESULTS FROM PILOT STUDY INDICATE THAT INOFER
GIVEN
TWICE DAILY CAN BE USED FOR TREATMENT OF IRON DEFICIENCY IN
HEART FAILURE PATIENTS WITHOUT HAVING ANEMIA
Source text for Eikon: ID:nWkrpKmSs
Further company coverage: DBPHAb.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University